Bo Chen News Today

Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the Chinas NMPA...

CHENGDU, China, March 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its 2023 annual results, along with recent

Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the Chinas NMPA...

One-time autonomous trucking leader TuSimple took the next step in its pullout from the U.S. market by voluntarily delisting from the Nasdaq. The post Autonomous truck developer TuSimple going private appeared first on FreightWaves.

  COPENHAGEN, Denmark and HANGZHOU, China, August 31, 2023 / B3C newswire / -- MC2 Therapeutics, Ltd (“MC2”), a wholly owned subsidiary of MC2 Therapeutics A/S and Hangzhou Zhongmei Huadong Pharmaceutical Co (“Huadong”), a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announced today a...

Learn about the top tech creations — and the Marylanders behind them — recognized during a recent event at the University of Maryland, College Park.

Investegate announcements from AstraZeneca PLC, AstraZeneca enters agreement with KYM for CMG901

/PRNewswire/ -- Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) and Lepu Biopharma Co., Ltd, (Stock Code: 02157.HK) today jointly announce a global...

HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the licence agreement, AstraZeneca will be responsible for the research, development, manufacture...

TuSimple wants to revolutionize long-haul freight in the U.S.